| Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)–a subgroup analysis of the ARIES-E clinical trial A Fischer, CP Denton, M Matucci-Cerinic, H Gillies, C Blair, J Tislow, ... Respiratory Medicine 117, 254-263, 2016 | 37 | 2016 |
| Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic … S Shapiro, F Torres, J Feldman, A Keogh, M Allard, C Blair, H Gillies, ... Respiratory Medicine 126, 84-92, 2017 | 22 | 2017 |
| Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial KR Patel, CJ Blair, JD Tislow Pulmonary Circulation 8 (4), 2045894018797273, 2018 | 4 | 2018 |
| Hepatic safety of ambrisentan and tadalafil alone and in combination-an analysis of the AMBITION trial K Patel, C Blair, J Tislow, K Miller PHARMACOTHERAPY 36 (12), E273-E273, 2016 | | 2016 |
| Ambrisentan Dose Migration over 3 Years in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (CTD-PAH) J Tislow, C Blair, H Gillies ARTHRITIS & RHEUMATOLOGY 67, 2015 | | 2015 |
| Categorical Change in 6MWD in Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension Receiving Ambrisentan over 3-Years. A Fischer, VD Steen, S Nathan, H Gillies, J Tislow, C Blair ARTHRITIS & RHEUMATOLOGY 66, S368-S369, 2014 | | 2014 |
